DOP2017000279A - Inhibidores de tirosina-cinasas - Google Patents

Inhibidores de tirosina-cinasas

Info

Publication number
DOP2017000279A
DOP2017000279A DO2017000279A DO2017000279A DOP2017000279A DO P2017000279 A DOP2017000279 A DO P2017000279A DO 2017000279 A DO2017000279 A DO 2017000279A DO 2017000279 A DO2017000279 A DO 2017000279A DO P2017000279 A DOP2017000279 A DO P2017000279A
Authority
DO
Dominican Republic
Prior art keywords
kinase inhibitors
thyrosine
compounds
tyrosine kinase
btk
Prior art date
Application number
DO2017000279A
Other languages
English (en)
Inventor
Goldstein David
Owens Timothy
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of DOP2017000279A publication Critical patent/DOP2017000279A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Diabetes (AREA)

Abstract

La presente divulgación proporciona compuestos que son inhibidores de tirosina-cinasas, en particular inhibidores de la tirosina-cinasa de Bruton (BTK), y, por lo tanto, son útiles para el tratamiento de enfermedades que se pueden tratar mediante la inhibición de BTK tales como el cáncer, enfermedades autoinmunitarias, inflamatorias y tromboembólicas. También se proporcionan composiciones farmacéuticas que contienen tales compuestos y procesos para preparar tales compuestos.
DO2017000279A 2015-06-03 2017-12-01 Inhibidores de tirosina-cinasas DOP2017000279A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562170547P 2015-06-03 2015-06-03
US201562271689P 2015-12-28 2015-12-28

Publications (1)

Publication Number Publication Date
DOP2017000279A true DOP2017000279A (es) 2018-04-15

Family

ID=56118090

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000279A DOP2017000279A (es) 2015-06-03 2017-12-01 Inhibidores de tirosina-cinasas

Country Status (33)

Country Link
US (4) US20180162861A1 (es)
EP (3) EP3912979A1 (es)
JP (2) JP6646072B2 (es)
KR (3) KR20240070721A (es)
CN (2) CN106459049B (es)
AU (2) AU2016270973B2 (es)
CA (1) CA2987335A1 (es)
CL (2) CL2017003073A1 (es)
CO (1) CO2017012947A2 (es)
CR (1) CR20170593A (es)
DK (1) DK3303334T3 (es)
DO (1) DOP2017000279A (es)
EA (1) EA039006B1 (es)
ES (1) ES2878030T3 (es)
HK (1) HK1252378A1 (es)
HR (1) HRP20211249T1 (es)
HU (1) HUE055419T2 (es)
IL (2) IL255946A (es)
LT (1) LT3303334T (es)
MX (2) MX2021006571A (es)
MY (1) MY190548A (es)
PE (1) PE20180521A1 (es)
PH (1) PH12017502203A1 (es)
PL (1) PL3303334T3 (es)
PT (1) PT3303334T (es)
RS (1) RS62290B1 (es)
SG (1) SG10201912443XA (es)
SI (1) SI3303334T1 (es)
TN (1) TN2017000501A1 (es)
TW (2) TWI810582B (es)
UA (1) UA124090C2 (es)
WO (1) WO2016196840A1 (es)
ZA (1) ZA201708667B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130619A1 (en) 2012-02-27 2013-09-06 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
MX361815B (es) 2012-09-10 2018-12-17 Principia Biopharma Inc Compuestos pirazolopirimidinicos como inhibidores de cinasas.
US10226782B2 (en) 2013-11-29 2019-03-12 Daizo Corporation Content-accommodating container, content-accommodating product using same, discharge product, and discharge device
KR20220027271A (ko) 2014-02-21 2022-03-07 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
WO2016100914A1 (en) 2014-12-18 2016-06-23 Gourlay Steven Treatment of pemphigus
CN106459049B (zh) * 2015-06-03 2020-11-27 普林斯匹亚生物制药公司 酪氨酸激酶抑制剂
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
US10358446B2 (en) * 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
CN109790164B (zh) * 2016-07-25 2022-01-25 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物
WO2018156901A1 (en) * 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
EP3789040A4 (en) * 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
AU2019309727B2 (en) 2018-07-25 2021-12-23 Novartis Ag NLRP3 inflammasome inhibitors
CN113194928A (zh) 2018-07-31 2021-07-30 罗索肿瘤学公司 (s)-5-氨基-3-(4-((5-氟-2-甲氧基苯甲酰胺基)甲基)苯基)-1-(1,1,1-三氟丙-2-基)-1h-吡唑-4-甲酰胺的喷雾干燥的分散体和制剂
AU2019340173B2 (en) * 2018-09-13 2024-02-08 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法
TW202140002A (zh) 2020-01-20 2021-11-01 美商健臻公司 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023520021A (ja) * 2020-03-30 2023-05-15 アイジーアイエー ファーマシューティカルズ インコーポレイテッド チロシンキナーゼ阻害剤の小児用製剤
WO2022033460A1 (zh) * 2020-08-10 2022-02-17 江苏恒瑞医药股份有限公司 Btk抑制剂治疗疾病的用途
PE20230855A1 (es) 2020-08-14 2023-05-29 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos
CN116507627A (zh) 2020-11-02 2023-07-28 勃林格殷格翰国际有限公司 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物
CA3201936A1 (en) 2020-12-10 2022-06-16 Minhua Chen Crystal form of tolebrutinib and preparation method thereof
IL303834A (en) * 2020-12-23 2023-08-01 Genzyme Corp 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
US20240217973A1 (en) * 2021-04-16 2024-07-04 Medshine Discovery Inc. Imidazopyridine compounds and use thereof
EP4328226A1 (en) * 2021-04-23 2024-02-28 Hangzhou Solipharma Co., Ltd. Tolebrutinib crystal form, amorphous form, preparation method therefor and use thereof
CN117412749A (zh) * 2021-05-21 2024-01-16 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
EP4353723A1 (en) 2021-06-11 2024-04-17 Genzyme Corporation Crystal form of tolebrutinib, preparation method therefor and use thereof
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
CN118302172A (zh) * 2021-09-24 2024-07-05 查德威克·唐纳森 用于通过粘膜递送药物的干粉可发泡制剂
TW202334146A (zh) 2021-12-21 2023-09-01 美商健臻公司 （ｒ）－１－（１－丙烯醯基哌啶－３－基）－４－胺基－３－（４－苯氧基苯基）－１ｈ－咪唑並［４，５－ｃ］吡啶－２（３ｈ）－酮及其衍生物的晶型
WO2023172663A1 (en) * 2022-03-09 2023-09-14 Teva Pharmaceuticals International Gmbh Solid state forms of tolebrutinib and of tolebrutinib salts
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
WO2023244587A1 (en) * 2022-06-14 2023-12-21 Genzyme Corporation Methods of making tolebrutinib
WO2023249980A1 (en) * 2022-06-22 2023-12-28 Genzyme Corporation Methods of making modified btk inhibitors
TW202421141A (zh) 2022-06-30 2024-06-01 美商健臻公司 用於多發性硬化症及重症肌無力之治療性酪胺酸激酶抑制劑
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
US20240173313A1 (en) 2022-10-11 2024-05-30 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for multiple sclerosis
WO2024099242A1 (zh) * 2022-11-07 2024-05-16 天津征程医药科技有限公司 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物
US20240238267A1 (en) 2022-12-20 2024-07-18 Genzyme Corporation Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
WO2024163542A2 (en) 2023-02-01 2024-08-08 Principia Biopharma Inc. Methods of diagnosing and treating multiple sclerosis

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
MX2007003078A (es) * 2004-09-14 2007-05-16 Novartis Vaccines & Diagnostic Compuestos de imidazoquinolina.
JP2008530113A (ja) * 2005-02-11 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシラミン置換イミダゾ［４，５−ｃ］環化合物および方法
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2011034907A2 (en) 2009-09-16 2011-03-24 Avila Therapeutics, Inc. Protein kinase conjugates and inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
DK2578585T3 (en) * 2010-05-31 2016-11-14 Ono Pharmaceutical Co PURINONDERIVAT AS BTK kinase inhibitor
MX355728B (es) * 2011-05-17 2018-04-27 Univ California Inhibidores de cinasas.
MX2013013331A (es) * 2011-05-17 2014-10-17 Principia Biopharma Inc Derivados de azaindol como inhibidores de tirosina-cinasas.
SI2710005T1 (sl) * 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
PL2786996T3 (pl) * 2011-11-29 2017-01-31 Ono Pharmaceutical Co., Ltd. Chlorowodorowa pochodna purynonu
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
CA2874461C (en) * 2012-06-18 2021-10-12 Principia Biopharma Inc. Formulations containing reversible covalent compounds
RS62233B1 (sr) 2012-07-11 2021-09-30 Blueprint Medicines Corp Inhibitori receptora fibroblast faktora rasta
MX361815B (es) * 2012-09-10 2018-12-17 Principia Biopharma Inc Compuestos pirazolopirimidinicos como inhibidores de cinasas.
US20140142099A1 (en) * 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN106459049B (zh) * 2015-06-03 2020-11-27 普林斯匹亚生物制药公司 酪氨酸激酶抑制剂
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
US10358446B2 (en) 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
KR102552653B1 (ko) 2023-07-07
SG10201912443XA (en) 2020-02-27
AU2020203447A1 (en) 2020-06-11
KR20240070721A (ko) 2024-05-21
CN106459049A (zh) 2017-02-22
CN113149983B (zh) 2024-03-29
RS62290B1 (sr) 2021-09-30
AU2020203447B2 (en) 2021-04-01
CN106459049B (zh) 2020-11-27
IL255946A (en) 2018-01-31
PH12017502203A1 (en) 2018-06-11
AU2016270973A1 (en) 2018-01-18
KR20180021730A (ko) 2018-03-05
ZA201708667B (en) 2024-07-31
JP6646072B2 (ja) 2020-02-14
TW202210478A (zh) 2022-03-16
EP3303334B1 (en) 2021-06-02
UA124090C2 (uk) 2021-07-21
US20170129890A1 (en) 2017-05-11
KR102666352B1 (ko) 2024-05-17
JP2018516935A (ja) 2018-06-28
MX2021006571A (es) 2022-08-25
US20230151012A1 (en) 2023-05-18
TWI732765B (zh) 2021-07-11
IL279258B (en) 2022-04-01
EA201792529A1 (ru) 2018-05-31
TW201713654A (zh) 2017-04-16
ES2878030T3 (es) 2021-11-18
MX2017015470A (es) 2018-08-15
MY190548A (en) 2022-04-27
DK3303334T3 (da) 2021-06-28
KR20220146657A (ko) 2022-11-01
CA2987335A1 (en) 2016-12-08
IL279258A (en) 2021-01-31
EP3303334A1 (en) 2018-04-11
PL3303334T3 (pl) 2021-11-08
JP2020073561A (ja) 2020-05-14
JP6985433B2 (ja) 2021-12-22
PT3303334T (pt) 2021-07-02
AU2016270973B2 (en) 2020-05-14
SI3303334T1 (sl) 2021-09-30
WO2016196840A1 (en) 2016-12-08
HK1252378A1 (zh) 2019-05-24
TWI810582B (zh) 2023-08-01
HRP20211249T1 (hr) 2021-11-12
BR112017025850A2 (pt) 2018-08-14
EP3912979A1 (en) 2021-11-24
LT3303334T (lt) 2021-07-12
EA039006B1 (ru) 2021-11-19
TN2017000501A1 (en) 2019-04-12
US20210171526A1 (en) 2021-06-10
HUE055419T2 (hu) 2021-11-29
CL2017003073A1 (es) 2018-06-08
CL2019002150A1 (es) 2019-11-29
PE20180521A1 (es) 2018-03-14
EP4112618A1 (en) 2023-01-04
US20180162861A1 (en) 2018-06-14
CN113149983A (zh) 2021-07-23
CO2017012947A2 (es) 2018-03-28
US9688676B2 (en) 2017-06-27
CR20170593A (es) 2018-05-14

Similar Documents

Publication Publication Date Title
CO2017012947A2 (es) Inhibidores de tirosina-cinasas
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2017011851A2 (es) Compuestos novedosos
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
NZ729603A (en) Heteroaryl compounds as btk inhibitors and uses thereof
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
EA032953B1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
UY37018A (es) Inhibidores bicíclicos de pad4
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
CL2019001092A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
CL2019001091A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.